| Systematic (IUPAC) name | |
|---|---|
| 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl- | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 288104-79-0 |
| ATC code | None |
| PubChem | CID 9849616 |
| ChemSpider | 8025329 |
| UNII | SF8R9VCB0X |
| ChEMBL | CHEMBL189676 |
| Chemical data | |
| Formula | C23H23BrCl2N4O |
| Mol. mass | 522.264 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis.[1] It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB1 antagonists or inverse agonists on the market or under development for this application,[2] so surinabant is at present mainly being developed as an anti-smoking drug,[3] with possible application in the treatment of other addictive disorders such as alcoholism.[4][5] Other potential applications such as treatment of ADHD have also been proposed.[6]
|
|||||||||||||||||||||||||||||||||||||||||||||||||